Approved indications: Invega Sustenna is FDA-approved for treatment of schizophrenia in adults and for schizoaffective disorder in adults, either alone or together with mood stabilizers or antidepressants.

Common off-label uses and evidence: Some clinicians may use paliperidone palmitate long-acting injections off-label for bipolar I disorder with psychotic features or other severe chronic psychotic conditions when a monthly injectable is needed; supporting data come mainly from smaller studies, case series, and extrapolation from oral paliperidone or risperidone, so evidence is more limited than for its approved uses.

Efficacy expectations and time course:

• With the recommended loading doses, many patients begin to notice improvement in psychotic or mood symptoms within the first 1–2 weeks, with further gains over several weeks to a few months.
• In longer-term trials in schizophrenia and schizoaffective disorder, Invega Sustenna significantly reduced relapse rates and prolonged time to relapse compared with placebo.
• Because it delivers steady medication levels and injections are supervised, it can be particularly effective for people who have difficulty taking oral antipsychotics consistently.

Comparison to similar drugs: Invega Sustenna provides efficacy comparable to other second-generation antipsychotics, with advantages of once-monthly dosing and no need for routine oral overlap; its side-effect profile is similar to risperidone, with relatively higher risk of elevated prolactin and moderate risk of weight and metabolic changes compared with agents like aripiprazole.

Typical adult dosing and route:

• Before starting, tolerability is usually checked with oral paliperidone or oral risperidone.
• Standard initiation for both schizophrenia and schizoaffective disorder is 234 mg intramuscularly into the deltoid muscle on day 1, then 156 mg into the deltoid on day 8.
• Starting 5 weeks after the first injection, a once-monthly maintenance dose is given in the deltoid or gluteal muscle; for schizophrenia the usual range is 39–234 mg, and for schizoaffective disorder 78–234 mg, with 117 mg a common maintenance dose.
• Injections are intramuscular only, given slowly as a single full-dose injection by a healthcare professional; doses are not split between sites or given intravenously or subcutaneously.

Special dosing considerations:

• Kidney function: In mild renal impairment (creatinine clearance about 50–79 mL/min), lower starting and maintenance doses are used (for example, 156 mg on day 1, 117 mg on day 8, and a usual maintenance of 78 mg with a maximum of 156 mg monthly). Invega Sustenna is not recommended in moderate or severe renal impairment (creatinine clearance <50 mL/min).
• Liver function: Based on oral data, no dose change is typically needed in mild to moderate hepatic impairment; use caution in severe hepatic impairment due to limited data.
• Older adults: Dosing is guided mainly by kidney function and tolerability; many older patients need lower doses.
• Not for children: Safety and effectiveness are not established in patients under 18 years.

How and when it is given: Injections can generally be scheduled at any time of day and do not depend on meals. The clinic will choose the correct needle size and injection site (deltoid or gluteal), and sites are rotated between sides.

Missed doses (overview): If a scheduled injection is missed by a few days, the next dose is often given as soon as possible at the usual strength; if more time has passed, the prescriber may need to adjust the dose or give one or two re-loading injections before resuming monthly dosing. Because the exact plan depends on how long it has been and what the previous dose was, patients should contact their clinician promptly rather than trying to approximate the schedule themselves.

Overdose: Receiving too much paliperidone (for example, extra injections or large amounts of oral paliperidone or risperidone on top of injections) can cause severe drowsiness, agitation, marked movement problems, very low blood pressure, or abnormal heart rhythms; emergency medical care is required, and treatment is supportive as there is no specific antidote.

Common side effects (often mild to moderate):

• Injection-site pain or redness.
• Sleepiness or fatigue, or sometimes insomnia.
• Dizziness, headache, anxiety, or restlessness (akathisia).
• Extrapyramidal symptoms (stiffness, tremor, slowed movement, muscle rigidity) and other movement problems.
• Weight gain, increased appetite, and metabolic changes such as increased blood sugar or lipids.
• Increased prolactin levels, which can cause breast enlargement, milk production, menstrual changes, or decreased sexual function.
• Nausea, constipation, or other mild gastrointestinal upset, and common infections such as colds.

These usually appear in the first days to weeks of treatment or after a dose increase and may lessen over time; any bothersome or persistent symptoms should be discussed with the prescriber.

Serious or rare adverse effects needing immediate medical attention:

• Neuroleptic malignant syndrome (very high fever, severe muscle stiffness, confusion, fast or irregular pulse, blood pressure changes).
• Severe or worsening uncontrolled movements, including signs of tardive dyskinesia (involuntary facial or body movements).
• Marked changes in blood sugar (excessive thirst, frequent urination, confusion, or signs of ketoacidosis), or rapid, substantial weight gain.
• Fainting, severe dizziness on standing, irregular heartbeat, chest pain, or symptoms of stroke (sudden weakness, trouble speaking, vision changes).
• Very low white blood cell counts (unusual infections, fever, sore throat that does not improve).
• Seizures, severe allergic reactions (rash, swelling of face or throat, trouble breathing), or prolonged, painful erections (priapism).
• Severe skin reactions or multi-organ hypersensitivity (rash with fever, swollen glands, or organ problems).

Warnings and precautions:

Invega Sustenna carries a boxed warning for increased risk of death in older adults with dementia-related psychosis and is not approved for this use. It should be used cautiously in people with cardiovascular disease, low blood pressure, a history of stroke or seizures, Parkinson’s disease or dementia with Lewy bodies, swallowing problems, or a history of low white blood cell counts. Dose reduction is needed in mild kidney impairment, and the drug is not recommended in moderate or severe renal impairment; no adjustment is usually required for mild to moderate liver impairment.

During pregnancy, especially in the third trimester, antipsychotics like paliperidone may cause withdrawal or movement symptoms in newborns, so risks and benefits must be weighed carefully. Paliperidone can pass into breast milk, so breastfeeding decisions should be individualized with the clinician. The drug is not approved for patients under 18 years of age.

Relative safety compared with other antipsychotics: Overall safety is similar to other second-generation antipsychotics, with particular attention to prolactin elevation and moderate metabolic risk, as seen with risperidone. Because it is long-acting, any serious adverse effect can persist for weeks after an injection, so careful monitoring is important, especially when starting or changing doses.

Reporting side effects and safety updates: Side effects can be reported to the FDA MedWatch program (by phone at 1-800-FDA-1088 or through the MedWatch website) or to the manufacturer. Updated safety information is provided in the full prescribing information and on the FDA’s drug safety communications web pages.

Key drug and substance interactions:

• Strong CYP3A4/P-glycoprotein inducers (such as carbamazepine, rifampin, and St. John’s wort) can lower paliperidone blood levels and reduce effectiveness; these are generally avoided during a dosing interval, or an oral formulation is used where doses can be adjusted.
• Other antipsychotics and dopamine-blocking drugs (including some antiemetics like metoclopramide) increase the risk of extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome and may add to prolactin elevation.
• Drugs that prolong the QT interval or disturb electrolytes (certain antiarrhythmics, macrolide and fluoroquinolone antibiotics, some antidepressants, and diuretics that cause low potassium or magnesium) may raise the risk of serious heart rhythm problems when combined.
• CNS depressants (benzodiazepines, opioids, alcohol, sedating antihistamines, sleep medicines) can have additive effects, leading to more sedation, dizziness, and possible respiratory depression.
• Antihypertensive agents and vasodilators can interact to increase the risk of low blood pressure and fainting, especially when starting or increasing doses.
• Levodopa and dopamine agonists (used in Parkinson’s disease) may be less effective because paliperidone blocks dopamine receptors.
• Medications that lower the seizure threshold (such as some antidepressants, tramadol, or bupropion) can add to seizure risk when used with Invega Sustenna.

Food, drink, and lifestyle interactions: There are no specific food restrictions, but alcohol should be limited or avoided due to additive sedative and coordination-impairing effects. Dehydration, overheating, or heavy exertion can make it harder to regulate body temperature while on antipsychotics and should be managed carefully.

Conditions and co-medications that require extra caution: A history of heart disease, arrhythmias, long-QT syndrome, stroke, seizures, diabetes or prediabetes, high cholesterol or triglycerides, obesity, Parkinson’s disease or dementia with Lewy bodies, swallowing problems, or prior low white blood cell counts all warrant careful risk–benefit assessment and closer monitoring. Concomitant use with other antipsychotics, strong enzyme inducers, or multiple QT-prolonging drugs should be weighed cautiously and minimized when possible.

Monitoring needs: Clinicians typically monitor weight, waist circumference, blood pressure (including standing and sitting), fasting glucose or A1c, and lipid panel at baseline and periodically. They may also check prolactin if symptoms arise, obtain a complete blood count in patients with previous low white blood cell counts, perform regular movement-disorder assessments, and consider an ECG in people with cardiac risk factors or on other QT-prolonging medicines.

Q: How often will I receive an Invega Sustenna injection?
A: Most people receive two starting injections one week apart, then one maintenance injection about once a month, with the exact dose and schedule set by their prescriber.

Q: How long does it take for Invega Sustenna to start working?
A: Some symptom relief may appear within the first week or two after the initial injections, but it can take several weeks to a few months to see the full benefit.

Q: What happens if I miss an injection appointment?
A: You should contact your clinic as soon as possible; depending on how long it has been since your last dose, your clinician may give the missed injection promptly or may need to adjust the dose or repeat the loading schedule.

Q: Will Invega Sustenna make me gain weight?
A: Weight gain is possible, especially in the first months of treatment, so your provider will usually monitor your weight and metabolic labs and may recommend diet, activity changes, or medication adjustments if needed.

Q: Can I drink alcohol or drive while using Invega Sustenna?
A: Alcohol can increase drowsiness and dizziness from the medication and is best limited or avoided, and until you know how the injections affect your alertness and coordination, you should be cautious with driving or operating machinery.

Q: What is the difference between Invega Sustenna and Invega Trinza or Invega Hafyera?
A: Invega Sustenna is the once-monthly paliperidone palmitate injection, while Invega Trinza (every three months) and Invega Hafyera (every six months) are longer-acting versions used only after a patient has been stabilized on Invega Sustenna for a period of time.

Storage: If you are given prefilled Invega Sustenna syringes to keep at home, store them at room temperature (about 59–86°F / 15–30°C), keep them in the original carton, protect them from extreme heat, cold, or light, and do not freeze.

Handling: Do not open the syringe or attach needles yourself; the medication is for single use and must be shaken, prepared, and injected only by a healthcare professional, and should be kept out of the reach of children.

Disposal: Used syringes and needles should go into an approved sharps container, not into household trash or recycling; if you end up with used or expired syringes at home, your clinic or pharmacy can tell you where to take a sharps container or how to follow local take-back or mail-back programs.